{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:53:40Z","timestamp":1773716020291,"version":"3.50.1"},"reference-count":186,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunological Investigations"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/08820139.2026.2613047","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T06:42:32Z","timestamp":1768200152000},"page":"602-637","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Immunotherapeutic Approaches in Colorectal Cancer: From Checkpoint Inhibitors to CAR-T Cell and Viral Vector Vaccines"],"prefix":"10.1080","volume":"55","author":[{"given":"Rajeev","family":"Ranjan","sequence":"first","affiliation":[{"name":"ISF College of Pharmacy","place":["Moga, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[{"name":"ISF College of Pharmacy","place":["Moga, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Kumar","sequence":"additional","affiliation":[{"name":"ISF College of Pharmacy","place":["Moga, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhawesh","family":"Kumar Mahato","sequence":"additional","affiliation":[{"name":"ISF College of Pharmacy","place":["Moga, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atreyee","family":"Sarkar","sequence":"additional","affiliation":[{"name":"ISF College of Pharmacy","place":["Moga, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratnesh","family":"Kumar Yadav","sequence":"additional","affiliation":[{"name":"ISF College of Pharmacy","place":["Moga, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gond","sequence":"additional","affiliation":[{"name":"ISF College of Pharmacy","place":["Moga, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreeharsha","family":"Nagaraja","sequence":"additional","affiliation":[{"name":"King Faisal University","place":["Al-Ahsa, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Raj Pal","sequence":"additional","affiliation":[{"name":"ISF College of Pharmacy","place":["Moga, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"Clinical study of chimeric CD(cluster of differentiation)133 antigen receptor-modified T cells in relapsed and\/or chemotherapy refractory malignancies. (2015b)."},{"key":"e_1_3_4_3_1","unstructured":"Colorectal cancer metastatic dMMR\/MSI-H immuno-therapy (COMMIT) study: A randomized Phase III study of mFOLFOX6\/bevacizumab\/atezolizumab combination versus single agent atezolizumab in the first-line treatment of patients with deficient DNA mismatch repair (dMMR)\/Microsatellite instability-high (MSI-H) metastatic colorectal cancer [N.R.G. Oncology Editor]. (2016c)."},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102345"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.01.009"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.14744\/ejmo.2024.56068"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1427428"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1687556"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111781"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2114254"},{"key":"e_1_3_4_11_1","unstructured":"Autologous immunotherapy with multi-target gene-modified CAR-T\/TCR-T cell for malignancies U. The First Affiliated Hospital of Zhengzhou (Ed.). (2018)."},{"key":"e_1_3_4_12_1","unstructured":"Avelumab combined with cetuximab and irinotecan for treatment refractory metastatic colorectal microsatellite stable cancer - a proof of concept open label non-randomized phase IIa study. The AVETUXIRI trial. (2018)."},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800961506150805145120"},{"key":"e_1_3_4_14_1","unstructured":"BACCI: A phase II randomized double-blind placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer. I. National cancer (Ed.). (2016)."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.09.050"},{"key":"e_1_3_4_17_1","volume-title":"PDQ cancer information summaries [Internet]","author":"Board P. A. T. E.","year":"2024","unstructured":"Board, P. A. T. E. (2024). Adult central nervous system tumors treatment (PDQ\u00ae). In PDQ cancer information summaries [Internet]. National Cancer Institute (US)."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/immuno5010009"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14204974"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2019.12.005"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.371"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2025.200333"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24283"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v12.i8.808"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/10732748251381441"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.016"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1329615"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0910"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123207"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i7.106723"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2361"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113277"},{"key":"e_1_3_4_35_1","unstructured":"A clinical research of CAR T cells Targeting EpCAM positive cancer. (2017a)."},{"key":"e_1_3_4_36_1","unstructured":"A clinical research of CAR T cells targeting HER2 positive cancer. (2016b)."},{"key":"e_1_3_4_37_1","unstructured":"A clinical research of chimeric antigen receptor (CAR) T cells targeting CEA positive canc (2015a)."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113882"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007409"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0278-6"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23354"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01124-9"},{"issue":"5","key":"e_1_3_4_43_1","first-page":"945","article-title":"Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo","volume":"9","author":"Deng X.","year":"2019","unstructured":"Deng, X., Gao, F., Li, N., Li, Q., Zhou, Y., Yang, T., Cai, Z., Du, P., Chen, F., & Cai, J. (2019). Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo. American Journal of Cancer Research, 9(5), 945.","journal-title":"American Journal of Cancer Research"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7030066"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.029"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.3323"},{"key":"e_1_3_4_47_1","unstructured":"An evaluation of the effectiveness and safety of decitabine combined with TQB2450 injection (PD-L1 monoclonal antibody) or decitabine + anlotinib combined with TQB2450 injection in the treatment of PD-1 monoclonal antibody-resistant digestive system tumors i\/phase ii clinical study. (2020a)."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i9.1136"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.574860"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08774-2"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.10.040"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591359"},{"key":"e_1_3_4_53_1","unstructured":"A first in human phase I trial of binary oncolytic adenovirus in combination with HER2-specific autologous CAR T cells in patients with advanced HER2 positive solid tumors. I. The Methodist Hospital Research (Ed.). (2018c)."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1676473"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115997"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0183"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132125"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108198"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.17"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01052"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae013"},{"key":"e_1_3_4_63_1","volume-title":"Urologic oncology: Seminars and original investigations","author":"Hahn A. W.","year":"2017","unstructured":"Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017). PD-1 checkpoint inhibition: Toxicities and management. In Urologic oncology: Seminars and original investigations (pp. 701\u2013707). Elsevier."},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00955-w"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01485-z"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30239-5"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205090"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.673"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032314"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1675807"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611789"},{"key":"e_1_3_4_72_1","unstructured":"Immunotherapy for peritoneal carcinomatosis (IPC) - a phase I study of the safety and efficacy of anti-CEA CAR-T cell intraperitoneal infusions for treatment of CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites. (2018d)."},{"key":"e_1_3_4_73_1","unstructured":"Immunotherapy with chimeric antigen receptor-modified T cells for MUC1 positive advanced refractory solid tumor H. [The First People\u2019s Hospital of and H. Hefei Binhu (Ed.). (2015c)."},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1680636"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S253369"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109745"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i17.4275"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.01.17"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1515057"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12539"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.14348\/molcells.2022.2056"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2024.2787"},{"key":"e_1_3_4_83_1","volume-title":"Understanding the role of T cell mediated immune responses in cancer immunotherapies","author":"Konda P.","year":"2022","unstructured":"Konda, P. (2022). Understanding the role of T cell mediated immune responses in cancer immunotherapies. Dalhousie University."},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638873"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887380"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00431-4"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.030"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00323-z"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01015"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.53388\/BMEC2026011"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2143698"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118565"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.08.29"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.11.011"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology12020287"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0479-7"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.982461"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211002018"},{"key":"e_1_3_4_102_1","unstructured":"Menon G. & Cagir B. (2025). Colon Cancer. In StatPearls. StatPearls Publishing Copyright \u00a9 2025 StatPearls Publishing LLC. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470380\/"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v129.10710"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom15091304"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041022"},{"key":"e_1_3_4_106_1","unstructured":"A multicenter open-label phase 2 study of lenvatinib (E7080\/MK-7902) plus pembrolizumab (MK-3475) in previously treated subjects with selected solid tumors (LEAP-005) [I. Eisai (Ed.). (2019a)."},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13070689"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202426047"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887189"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8043"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33966"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.01.001"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189848"},{"key":"e_1_3_4_115_1","unstructured":"An open-label dose escalation phase I study to assess the safety and clinical activity of multiple hepatic transarterial administrations of NKR-2 in patients with unresectable liver metastases from colorectal cancer. (2017b)."},{"key":"e_1_3_4_116_1","unstructured":"An open-label phase I study to assess the safety and clinical activity of multiple doses of NKR-2 administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer. (2017c)."},{"key":"e_1_3_4_117_1","unstructured":"An open-label phase I study to assess the safety of multiple doses of CYAD-101 administered after standard FOLFOX or FOLFIRI chemotherapy in patients with unresectable metastatic colorectal cancer. (2018e)."},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103038"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2025.1612186"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9"},{"key":"e_1_3_4_122_1","unstructured":"Pembrolizumab in combination with XELOX bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: A proof of concept study. (2020b)."},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111854"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2379062"},{"key":"e_1_3_4_125_1","unstructured":"A phase 2 clinical trial of Nivolumab or Nivolumab combinations in recurrent and metastatic microsatellite instability high (MSI-H) and non-MSI-H colon cancer. (2013)."},{"key":"e_1_3_4_126_1","unstructured":"A phase Ib clinical trial to evaluate the efficacy and safety of TQB2618 injection combined with TQB2450 injection in patients with advanced solid tumors. (2022)."},{"key":"e_1_3_4_127_1","unstructured":"A phase IB study of pembrolizumab in combination with pemetrexed and oxaliplatin in patients with chemo-refractory metastatic colorectal cancer [S. Merck et al. (Ed.). 2015. (2018f)."},{"key":"e_1_3_4_128_1","unstructured":"Phase Ib study of TQB2450 combined with anlotinib in patients with advanced solid tumors. (2019b)."},{"key":"e_1_3_4_129_1","unstructured":"Phase Ib trial of CAR-T hepatic artery infusions followed by selective internal radiation therapy (SIRT) with yttrium-90 sir-Spheres\u00ae for CEA-expressing liver metastases [M. Sirtex (Ed.). (2015d)."},{"key":"e_1_3_4_130_1","unstructured":"Phase Ib trial of CAR-T Hepatic artery infusions or pancreatic venous infusions delivered with the surefire infusion system (SIS) for CEA-Expressing liver metastases or pancreas cancer [D. University of Colorado and I. Sorrento Therapeutics (Ed.). (2016d)."},{"key":"e_1_3_4_131_1","unstructured":"A phase I\/II phase evaluating the effectiveness and safety of CDK4\/6 inhibitor (TQB3616) combined with PD-L1 monoclonal antibody (TQB2450) in the treatment of PD-1\/PD-L1 monoclonal antibody resistance and abnormal cell cycle digestive system tumors. (2021)."},{"key":"e_1_3_4_132_1","unstructured":"Phase I\/II study of EGFR CART cells for patients with metastatic colorectal cancer [S. The Beijing Pregene and L. Technology Company (Ed.). (2017d)."},{"key":"e_1_3_4_133_1","unstructured":"Phase I\/II study of EGFR-IL12-CART cells for patients with metastatic colorectal cancer. The Pregene biotechnology company (Ed.). (2018h)."},{"key":"e_1_3_4_134_1","unstructured":"A phase III study of pembrolizumab (MK-3475) vs. chemotherapy in microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) stage IV colorectal carcinoma (KEYNOTE-177). (2015f)."},{"key":"e_1_3_4_135_1","unstructured":"A phase I\/II study of PI3Kinase inhibition (Copanlisib) and anti-PD-1 antibody nivolumab in relapsed\/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer [Bayer and S. Bristol-Myers (Ed.). (2018i)."},{"key":"e_1_3_4_136_1","unstructured":"Phase I\/II trial of encorafenib binimetinib and nivolumab in microsatellite stable BRAF V600E metastatic colorectal cancer [Pfizer and S. Bristol-Myers (Ed.). (2019c)."},{"key":"e_1_3_4_137_1","unstructured":"Phase II multicenter trial of panitumumab nivolumab and ipilimumab for KRAS\/NRAS\/BRAF wild-type MSS refractory metastatic colorectal adenocarcinoma [Amgen and S. Bristol-Myers (Ed.). (2018g)."},{"key":"e_1_3_4_138_1","unstructured":"Phase II study of avelumab and cetuximab and modified folfoxiri as initial therapy for ras wild-type unresectable metastatic colorectal cancer patients. (2020c)."},{"key":"e_1_3_4_139_1","unstructured":"A phase II study of pembrolizumab (MK-3475) as monotherapy in subjects with previously treated locally advanced unresectable or metastatic (stage IV) mismatched repair deficient or microsatellite instability-high colorectal carcinoma (KEYNOTE-164). (2015e)."},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1070"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172898"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.01118"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.961796"},{"key":"e_1_3_4_144_1","volume-title":"Defining the role of T cell receptor: Self-peptide\/MHC class II interactions in directing CD4+ T cell fate, function, and pathogenic potential","author":"Rodriguez D. M.","year":"2022","unstructured":"Rodriguez, D. M. (2022). Defining the role of T cell receptor: Self-peptide\/MHC class II interactions in directing CD4+ T cell fate, function, and pathogenic potential. The University of Chicago."},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1112276"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030371"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12477"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030863"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101430"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.670"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2025.102036"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_3_4_153_1","unstructured":"A single-arm pilot clinical study of chimeric antigen receptor T cells combined with interventional therapy in advanced liver malignancy [C. Shanghai Cancer Hospital (Ed.). (2016e)."},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1071223"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1159\/000488918"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.07.055"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00600-4"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010182"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0412-8"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02497-z"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2019.09.018"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0009-4"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02407-8"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i48.5418"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2020.03.10"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03358-y"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02729-7"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3410"},{"key":"e_1_3_4_169_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035276"},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00943-6"},{"key":"e_1_3_4_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.011"},{"key":"e_1_3_4_172_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2020.03.03"},{"key":"e_1_3_4_173_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226"},{"key":"e_1_3_4_174_1","doi-asserted-by":"publisher","DOI":"10.14744\/ejmo.2023.46574"},{"key":"e_1_3_4_175_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12020258"},{"key":"e_1_3_4_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2025.112758"},{"key":"e_1_3_4_177_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0102-y"},{"key":"e_1_3_4_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.010"},{"key":"e_1_3_4_179_1","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5RU0222-082R"},{"key":"e_1_3_4_180_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1616414"},{"key":"e_1_3_4_181_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1641518"},{"key":"e_1_3_4_182_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102762"},{"key":"e_1_3_4_183_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.70958"},{"key":"e_1_3_4_184_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035323"},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411673"},{"key":"e_1_3_4_186_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S173201"},{"key":"e_1_3_4_187_1","first-page":"47628","article-title":"NKG2D and its ligands: One for all","author":"Zingoni A.","year":"2020","unstructured":"Zingoni, A., et al. (2020). NKG2D and its ligands: One for all. Emerging Concepts on the NKG2D Receptor-NKG2D Ligand Axis in Health and Diseases, 47628.","journal-title":"Emerging Concepts on the NKG2D Receptor-NKG2D Ligand Axis in Health and Diseases"}],"container-title":["Immunological Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08820139.2026.2613047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:18:34Z","timestamp":1773713914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/08820139.2026.2613047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":186,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/08820139.2026.2613047"],"URL":"https:\/\/doi.org\/10.1080\/08820139.2026.2613047","relation":{},"ISSN":["0882-0139","1532-4311"],"issn-type":[{"value":"0882-0139","type":"print"},{"value":"1532-4311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}